Trials / Completed
CompletedNCT00101985
Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)
An Eight-week, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects With Irritable Bowel Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 741 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effectiveness and safety of the investigational drug talnetant in treating subjects with irritable bowel syndrome (IBS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | talnetant |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2005-07-01
- Completion
- 2005-07-01
- First posted
- 2005-01-19
- Last updated
- 2015-04-13
Locations
135 sites across 10 countries: United States, Australia, Canada, France, Germany, Netherlands, South Africa, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00101985. Inclusion in this directory is not an endorsement.